Entrada Therapeutics
TRDA
38 hedge funds and large institutions have $302M invested in Entrada Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 15 reducing their positions, and 17 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more capital invested
Capital invested by funds: $243M → $302M (+$59M)
3.82% less ownership
Funds ownership: 82.81% → 78.99% (-3.8%)
21% less funds holding
Funds holding: 48 → 38 (-10)
53% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 17
67% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.52M |
| 2 |
CA
CHI Advisors
New York
|
+$1.24M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$1.22M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$979K |
| 5 |
Millennium Management
New York
|
+$580K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.64M |
| 2 |
BlackRock
New York
|
-$2.89M |
| 3 |
SG
StepStone Group
La Jolla,
California
|
-$958K |
| 4 |
State Street
Boston,
Massachusetts
|
-$918K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$576K |
TRDA Hedge Fund Activity: Q2 2022 in Review
38 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q2 2022, worth a combined $302M — up 24% from $243M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of TRDA and 8 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 5 added.
The largest buyer was Vanguard Group, adding an estimated $2.52M. The largest seller was Wellington Management Group, cutting an estimated $7.64M.
- 38 institutional investors held Entrada Therapeutics (TRDA) as of Q2 2022, down from 48 in Q1 2022.
- Funds reported $302M of Entrada Therapeutics stock for Q2 2022, up 24% quarter-over-quarter.
- 8 funds opened new Entrada Therapeutics positions in Q2 2022 and 17 closed out, a net change of -9 holders.
- The largest Entrada Therapeutics buyer in Q2 2022 was Vanguard Group, an estimated $2.52M added.
- The largest Entrada Therapeutics seller in Q2 2022 was Wellington Management Group, an estimated $7.64M sold.
Based on aggregated 13F filings for Q2 2022.